NEW R&D MODEL needed for antibiotic innovation is proposed: public-private partnerships. We all know that we have over-used antibiotics. And that resistant strains (Superbugs) are emerging. And that the pipeline is sparse because Big Pharma has left the sector. This call for a new initiative is in line with other similar open innovation public-private initiatives worldwide and let’s hope it is adopted.
http://lnkd.in/cRt2Hb
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022